Created On: 2020-07-15
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27993
The parties desire for Licensee to develop, manufacture, market, distribute and sell a product for treating or preventing influenza virus and/or infection, such as a vaccine comprising antigenic determinants of an influenza virus, like FluogenÂ®, which includes a proprietary adjuvant developed by Licensor.
IPSCIO Record ID: 4244
VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Companyâ€™s VLPs resemble the virus they were engineered to mimic, but lack the genetic material to replicate the virus and its single-use bioprocessing production technology uses insect cells rather than chicken eggs or mammalian cells.
The Licensorâ€™s current product targets include VLP vaccines against seasonal and pandemic (including H5N1) influenza and a recombinant nanoparticle vaccine against Respiratory Syncytial Virus (RSV).
The upfront payment has been deferred and will be recognized as revenue when certain obligations in the agreement are satisfied.
IPSCIO Record ID: 7238
Neuraminidase inhibitors work against influenza by preventing viruses from being released from infected cells and subsequently infecting further cells. Neuraminidase inhibitors are usually prescribed to patients presenting with flu-like symptoms during epidemic periods to reduce symptoms or prevent spread of the virus.
IPSCIO Record ID: 299287
The patents include Improved vaccines and methods for using the same; Novel vaccines against multiple subtypes of influenza virus; Influenza Nucleic acid molecules and vaccines made therefrom; and, Nucleic acid molecule encoding concensus influenza a hemagglutinin H!
SynConâ„¢ technology enables the design of â€œuniversalâ€ DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza.
IPSCIO Record ID: 179238
Liposome encapsulation is a process designed to entrap and deliver various useful materials. Prior to the development of the Novavax Technologies, the most commonly used technology, phospholipid liposome encapsulation, had a limited capacity to encapsulate anything other than materials that can be dissolved or suspended in water. Phospholipid liposomes are man-made, microscopic spheres that are usually formed through a multi-step process, which generally includes the mixing of water, organic solvents and phospholpids. Most phospholipid-based liposomes are produced from materials that are expensive and may require the use of potentially hazardous organic solvents. The standard, multi-step phospholipid manufacturing process yields small quantities of expensive, less stable vesicles with limited cargo capacity.
IPSCIO Record ID: 394
5,554,372 (subject to U.S. government regulations)
Pending application 90/104,088